Why the study?
CAD is causally associated with lipid metabolism changes, prompting this assessment of lipid profiles in patients with chronic coronary syndrome.
Cross-Sectional (n=100)
No
A vast majority of patients with chronic coronary syndrome are not achieving guideline-directed LDL-C targets, highlighting a significant gap in secondary prevention and lipid management.
Cross-sectional data associate dyslipidemia patterns with chronic coronary syndrome; leaves open whether targeted lipid interventions alter outcomes.
Background: Coronary artery disease (CAD) has been proven to be causally associated to genetically defined and metabolically produced changes in lipid metabolism, as seen in numerous kinds of dyslipidemia. Objective: The aim of the present study was to assess the lipid profile in patients with chronic coronary syndrome. Patients and Methods: A hospital based cross-sectional study was conducted at Sohag University Hospital and included 100 patients with chronic coronary syndrome. The examined if our patients could achieve the target lipid profile level of their group according to 2019 ESC/EAS Guidelines for the management of dyslipidaemia. History of CAD and family history were taken. Clinical presentation and body mass index (BMI) were assessed. Finally, lifestyle, drug history (lipid lowering drug, anti HTN drug and anti-platelets drugs), dietary intake assessment and physical exercise were evaluated. Results: Patients had a mean HDL-C level of 39.4 91mg/dL, a mean total cholesterol level of 188.91mg/dL, a mean LDL-C level of 119.67mg/dL and a mean triglyceride level of 149.15mg/dL. HDL-C was significantly lower for non-statin therapy group compared to statin therapy group (P<0.001), while triglycerides and vLDL were significantly higher non-statin therapy group compared to statin therapy group (P<0.001). Only 8% of patients achieved target LDL-C according to 2019 ESC/EAS guidelines. Conclusion: Most of patients at Sohag University Hospital are not reaching the target LDL-C. Thus, more strict application of guidelines and investigating the predisposing factors for uncontrolled lipid profile, especially in patients with CAD, are urgently needed.
No takes yet. Share an insight, caveat, or question.
Farrag et al. (2023) conducted a cross-sectional in chronic coronary syndrome (n=100). Statin therapy vs. Non-statin therapy was evaluated on Achievement of target LDL-C according to 2019 ESC/EAS guidelines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: